GET THE FULL COMPANY
ANALYSIS BUNDLE FOR
Vor
Who owns Vor Biopharma?
Vor Biopharma went public on February 5, 2021, raising $203,000,000, shifting governance to institutional and retail investors and accelerating its eHSC clinical programs.
Major shareholders include specialized biotech funds and long-only institutions, reflecting concentrated expertise-driven ownership that shapes Vor’s strategic focus and clinical priorities.
Explore related strategic analysis: Vor Porter's Five Forces Analysis
Who Founded Vor?
Founders and early ownership of Vor centered on a PureTech Health incubation with Siddhartha Mukherjee as the scientific founder; initial control was concentrated in the incubator while external investors joined at Series A.
Scientific founder
Siddhartha Mukherjee provided the scientific vision for shielding healthy cells from targeted therapies, forming the intellectual core of the company.
Incubation lead
The company was conceptualized and incubated by PureTech Health, which supplied seed capital, management and lab resources at founding in 2016.
Initial ownership concentration
PureTech typically retained a majority stake; at seed stage its holdings commonly range between 60% and 80%.
Series A financing
In 2019 Vor raised $42,000,000 in a Series A led by 5AM Ventures with RA Capital, Casdin Capital and Insight Partners joining.
Early investors’ stakes
Series A investors acquired significant minority positions, subject to standard VC terms like four-year vesting for management shares and buy-sell clauses.
Governance and board control
Board composition reflected PureTech and 5AM influence through board seats and a voting agreement among preferred holders to align on developing the eHSC platform.
Early ownership evolution balanced PureTech’s majority incubator position with institutional investors from the Series A, shaping Vor Company ownership and governance going into clinical development.
Key ownership facts
Relevant points on who owns Vor and its early structure.
- PureTech Health acted as the parent company and majority seed-stage owner, typically holding between 60% and 80%.
- Series A in 2019 raised $42 million, led by 5AM Ventures with RA Capital, Casdin Capital and Insight Partners as participants.
- Management equity commonly followed a four-year vesting schedule; investor agreements included buy-sell clauses and voting covenants.
- Board seats were allocated to PureTech and 5AM to guide clinical milestones and maintain aligned control over Vor’s strategy.
Further detail on Vor Company ownership and business model appears in this related article: Revenue Streams & Business Model of Vor
Complete Vor Strategy Bundle
- 6 Full Frameworks, 1 Company – All Pre-Researched
- Each Framework Fully Sourced with Real Company Data
- Built for Strategy Courses, Case Studies & MBA Programs
- Adapt to Your Assignment – No Starting from Scratch
- 6 Frameworks: SWOT, PESTLE, Porter's, BMC, BCG and 4P's
How Has Vor’s Ownership Changed Over Time?
Key events reshaping Vor Company ownership include the 2021 IPO that issued 11.3 million shares at $18.00 per share, subsequent secondary sales by early investors, and steady institutional accumulation through 2022–2025 that shifted control from venture backers to large healthcare-focused asset managers.
| Stakeholder | Approx. Ownership | Notes |
|---|---|---|
| RA Capital Management | 14.8% | Largest holder; long-term commitment to trem-cel program |
| 5AM Ventures | 9.5% | Early venture investor retained significant position post-IPO |
| PureTech Health | 7.2% | Founding parent; sold portions to fund other ventures but retains strategic stake |
| FMR LLC (Fidelity) | ~6.0% | Top-tier asset manager with a material position |
| Other institutional holders (including Casdin) | ~34.5% | Specialized healthcare funds and mutual funds, driving institutional ownership to ~72% |
| Insiders (execs & directors) | 4.5% | Management-aligned ownership |
As of mid-2025 institutional ownership stands at approximately 72% of outstanding shares, leaving retail and insiders with the remainder; this concentration influences governance, liquidity, and share-price sensitivity around clinical readouts and SEC disclosures. For more context on competitive positioning, see Competitors Landscape of Vor
Ownership Dynamics to Watch
Concentration among healthcare-focused institutions signals confidence but raises volatility tied to clinical milestones and filings.
- Institutional ownership: ~72%
- Top holder: RA Capital at 14.8%
- Founding influence: PureTech retains 7.2%
- Insider stake: 4.5%
From PESTLE Factors to Full Strategy Bundle
- PESTLE + SWOT + Porter's + BCG + BMC + 4P's in One Bundle
- Every Strategic Angle Covered – Nothing Left to Research
- Pre-filled with Company-Specific Research
- No Missing Sections for Your Case Study
- One Download Covers Your Entire Company Analysis
Who Sits on Vor’s Board?
The Board of Directors at Vor Biopharma blends biotech scientific leadership with venture capital and institutional investor representation, chaired by Kush Parmar and including CEO Robert Ang and independent experts like David Scadden, aligning governance with clinical and capital strategies.
| Director | Role / Affiliation | Representative Interest |
|---|---|---|
| Kush Parmar | Chair; Managing Partner, 5AM Ventures | Early-stage investor |
| Robert Ang | Director; Chief Executive Officer | Management |
| Bharatt Chowrira | Director | Represents PureTech Health |
| David Scadden | Independent Director; Harvard regenerative medicine pioneer | Academic / scientific expertise |
Vor Company ownership and voting align with a one-share, one-vote common stock structure, but concentrated institutional holdings give outsized influence over strategic votes and capital allocation for Phase 1/2 trials.
Board composition and voting dynamics
The board mixes investors and scientists; major institutional holders effectively control key outcomes despite single-class voting.
- Top five institutional shareholders hold nearly 45% of voting power as of 2025
- Single-class common stock: each share = one vote
- No major proxy contests or activist campaigns recorded through 2025
- Major shareholders steered capitalization decisions for Phase 1/2 clinical programs
For further context on Vor Company structure and market positioning, see Target Market of Vor.
Vor Business Model + Strategy Bundle
- Ideal for Essays, Case Studies & Slides
- Get BCG, SWOT, PESTLE, Porter's, 4P's Mix & BMC Together
- Company-Specific Content Already Organized
- One Bundle Replaces Days of Independent Research
- Buy the Bundle Once. Use Across All Your Assignments
What Recent Changes Have Shaped Vor’s Ownership Landscape?
Between 2023 and early 2025 Vor Company ownership shifted amid a tight biotech funding market, with equity raises and passive index inflows reshaping the cap table and insider holdings.
| Event | Timing | Impact on Ownership |
|---|---|---|
| ATM facility and follow-on offering (~$50,000,000) | Late 2023 | Raised cash runway into late 2025; caused modest dilution of existing shareholders |
| Index fund accumulation (BlackRock, Vanguard) | 2024 | Collective passive ownership ~8%; reflects inclusion in biotech indices |
| Executive departures and insider share redistribution | 2023–2024 | Insider ownership rebalanced; CEO Robert Ang retained steady holding |
Analysts view the company as an acquisition candidate amid consolidation in cell and gene therapy; upcoming clinical data for trem-cel and VOR39 will likely drive the next ownership shifts between institutional investors, activists, or strategic buyers.
Funding actions
The late 2023 follow-on raised approximately $50,000,000 using ATM and follow-on placements to extend runway.
Passive investor trend
Passive index funds increased exposure in 2024, now holding about 8% combined, altering the ownership mix.
Leadership changes
Departures of early executives redistributed insider shares while CEO Robert Ang maintained a consistent stake.
Strategic implications
Focus on key clinical milestones for trem-cel and VOR39 through 2025 will determine whether ownership shifts toward institutions, activists, or a strategic acquirer; see more in Mission, Vision & Core Values of Vor.
From Five Forces to Full Company Analysis
- Includes SWOT, PESTLE, BMC, BCG and 4P's
- Pre-Researched with Company-Specific Data
- Best Value for a Complete Analysis
- Ready to Adapt for Your Case Study
- Ready for Essays and Slidesd
- What is Brief History of Vor Company?
- What is Competitive Landscape of Vor Company?
- What is Growth Strategy and Future Prospects of Vor Company?
- How Does Vor Company Work?
- What is Sales and Marketing Strategy of Vor Company?
- What are Mission Vision & Core Values of Vor Company?
- What is Customer Demographics and Target Market of Vor Company?
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.